- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Carboplatin, Cetuximab, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Survey Administration
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 63
- States / cities
- Beverly Hills, California • Los Angeles, California • Newark, Delaware + 48 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 94
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
- Interventions
- MEDI0457, Durvalumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Oropharyngeal Cancer
- Interventions
- Transoral Robotic Surgery (TORS), Modified Barium Swallow (MBS), Questionnaires
- Procedure · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Squamous Cell Carcinoma, Oropharynx Cancer
- Interventions
- Intensity modulated radiotherapy (IMRT), PET-MRI
- Radiation · Diagnostic Test
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- HPV-Related Squamous Cell Carcinoma
- Interventions
- FMISO-PET Scan, Chemoradiation, Assessments
- Diagnostic Test · Combination Product · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 6 more
- Conditions
- Oropharyngeal Squamous Cell Carcinoma (OPSCC), HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- MRI
- Diagnostic Test
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B)
- Diagnostic Test · Behavioral · Radiation + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
- Interventions
- E7 TCR-T cells, Aldesleukin
- Biological · Drug
- Lead sponsor
- Christian Hinrichs
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • New Brunswick, New Jersey
- Conditions
- Oropharyngeal Cancer, HPV-Related Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- NavDx
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2031
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- ADXS11-001 (ADXS-HPV)
- Biological
- Lead sponsor
- Andrew Sikora
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx
- Interventions
- paclitaxel, carboplatin, intensity-modulated radiation therapy, quality-of-life assessment
- Drug · Radiation · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care, Circulating Tumor DNA test (ctDNA test)
- Other · Radiation · Diagnostic Test
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Interventions
- Assessment of Oral HPV Infection
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Drug
- Lead sponsor
- Theravectys S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma
- Conditions
- Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer, Human Papilloma Virus, Squamous Cell Carcinoma
- Interventions
- Lidocaine 1% Injectable Solution
- Drug
- Lead sponsor
- Ryan Carey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck
- Interventions
- F-FMISO PET/CT Scan, 30 Gy over 3 weeks, Cisplatin, Carboplatin, 5Fluorouracil, Proton Therapy
- Diagnostic Test · Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
- Conditions
- Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum
- Radiation · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Mutation, Head and Neck Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Head and Neck Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
- Interventions
- BGJ398
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Interventions
- HB-201, HB-202, Carboplatin, Paclitaxel, Transoral Robotic Surgery
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Basaloid Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Posterior Tongue Squamous Cell Carcinoma, Soft Palate Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Tonsillar Squamous Cell Carcinoma
- Interventions
- Intensity-Modulated Radiation Therapy, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Radiation · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- 44 doses of radiation, 54 doses of radiation
- Radiation
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Not listed
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Carmel, Indiana • Indianapolis, Indiana
- Conditions
- Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
- Interventions
- Modified Barium Swallow (MBS), Swallowing Questionnaire, Symptom Questionnaire, Video-Strobe Procedure, MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning, Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning, Intensity Modulated Radiotherapy (IMRT)
- Procedure · Behavioral · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Carboplatin, Cemiplimab, Cisplatin, Computed Tomography, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Salvage Surgery
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 113
- States / cities
- Tucson, Arizona • Los Angeles, California • Palo Alto, California + 83 more
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Paclitaxel, Positron Emission Tomography, Questionnaire Administration
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio